4//SEC Filing
Venrock Healthcare Capital Partners III, L.P. 4
Accession 0001415889-24-001941
CIK 0001348911other
Filed
Jan 28, 7:00 PM ET
Accepted
Jan 29, 7:07 PM ET
Size
21.5 KB
Accession
0001415889-24-001941
Insider Transaction Report
Form 4
VHCP Co-Investment Holdings III, LLC
10% Owner
Transactions
- Purchase
Common Stock
2024-01-29$14.22/sh+80,600$1,146,132→ 4,650,584 total(indirect: By Funds) - Purchase
Common Stock
2024-01-25$12.73/sh+7,030$89,492→ 4,565,810 total(indirect: By Funds) - Purchase
Common Stock
2024-01-26$12.98/sh+4,174$54,179→ 4,569,984 total(indirect: By Funds)
Koh Bong Y
10% Owner
Transactions
- Purchase
Common Stock
2024-01-26$12.98/sh+4,174$54,179→ 4,569,984 total(indirect: By Funds) - Purchase
Common Stock
2024-01-25$12.73/sh+7,030$89,492→ 4,565,810 total(indirect: By Funds) - Purchase
Common Stock
2024-01-29$14.22/sh+80,600$1,146,132→ 4,650,584 total(indirect: By Funds)
Transactions
- Purchase
Common Stock
2024-01-25$12.73/sh+7,030$89,492→ 4,565,810 total(indirect: By Funds) - Purchase
Common Stock
2024-01-26$12.98/sh+4,174$54,179→ 4,569,984 total(indirect: By Funds) - Purchase
Common Stock
2024-01-29$14.22/sh+80,600$1,146,132→ 4,650,584 total(indirect: By Funds)
Transactions
- Purchase
Common Stock
2024-01-25$12.73/sh+7,030$89,492→ 4,565,810 total(indirect: By Funds) - Purchase
Common Stock
2024-01-29$14.22/sh+80,600$1,146,132→ 4,650,584 total(indirect: By Funds) - Purchase
Common Stock
2024-01-26$12.98/sh+4,174$54,179→ 4,569,984 total(indirect: By Funds)
VHCP Management III, LLC
10% Owner
Transactions
- Purchase
Common Stock
2024-01-25$12.73/sh+7,030$89,492→ 4,565,810 total(indirect: By Funds) - Purchase
Common Stock
2024-01-26$12.98/sh+4,174$54,179→ 4,569,984 total(indirect: By Funds) - Purchase
Common Stock
2024-01-29$14.22/sh+80,600$1,146,132→ 4,650,584 total(indirect: By Funds)
VHCP Management EG, LLC
10% Owner
Transactions
- Purchase
Common Stock
2024-01-25$12.73/sh+7,030$89,492→ 4,565,810 total(indirect: By Funds) - Purchase
Common Stock
2024-01-26$12.98/sh+4,174$54,179→ 4,569,984 total(indirect: By Funds) - Purchase
Common Stock
2024-01-29$14.22/sh+80,600$1,146,132→ 4,650,584 total(indirect: By Funds)
Shah Nimish P
10% Owner
Transactions
- Purchase
Common Stock
2024-01-26$12.98/sh+4,174$54,179→ 4,569,984 total(indirect: By Funds) - Purchase
Common Stock
2024-01-25$12.73/sh+7,030$89,492→ 4,565,810 total(indirect: By Funds) - Purchase
Common Stock
2024-01-29$14.22/sh+80,600$1,146,132→ 4,650,584 total(indirect: By Funds)
Footnotes (7)
- [F1]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.64 to $12.75 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- [F2]Consists of (i) 990,984 shares held by Venrock Healthcare Capital Partners III, L.P. ("VHCP3"); (ii) 99,132 shares held by VHCP Co-Investment Holdings III,LLC ("VHCP Co-3"); and (iii) 3,475,694 shares held by Venrock Healthcare Capital Partners EG, L.P. ("VHCP EG").
- [F3]VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own these shares. VHCP Management EG, LLC ("VHCPMEG") is the general partner of VHCPEG and may be deemed to beneficially own these shares. Bong Koh and Nimish Shah are the voting members of VHCPM3 and VHCPMEG and may be deemed to beneficially own these shares. Each of VHCPM3, VHCPMEG and Messrs. Koh and Shah expressly disclaims beneficial ownership over these shares except to the extent of its or his indirect pecuniary interest therein.
- [F4]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.96 to $12.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- [F5]Consists of (i) 992,081 shares held by VHCP3; (ii) 99,242 shares held by VHCP Co-3; and (iii) 3,478,661 shares held by VHCP EG.
- [F6]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.51 to $14.43 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- [F7]Consists of (i) 1,013,271 shares held by VHCP3; (ii) 101,361 shares held by VHCP Co-3; and (iii) 3,535,952 shares held by VHCP EG.
Documents
Issuer
KalVista Pharmaceuticals, Inc.
CIK 0001348911
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001738048
Filing Metadata
- Form type
- 4
- Filed
- Jan 28, 7:00 PM ET
- Accepted
- Jan 29, 7:07 PM ET
- Size
- 21.5 KB